Earlier this week, investors following the pharmaceutical industry may have been surprised to hear that Pfizer was interested in acquiring AstraZeneca. However, the billion-dollar buyout news didn't stop there.
Yesterday, shares of Allergan (UNKNOWN:AGN.DL), the company best-known for its key product Botox, popped more than 15% on news that Valeant Pharmaceuticals (NYSE:VRX) is keen on acquiring it. In the following video, analysts Max Macaluso and Michael Douglass discuss this potential deal, and its implications for investors.
Max Macaluso, Ph.D. has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.